This session will provide an overview of the history and goals of the RWE Transparency Initiative and why it is timely, as well as its work to date, and the key points of its recent white paper. It will cover fundamental aspects of this issue including: potential registration sites, issues of credibility and transparency, characteristics of studies recommended for registration (ie, hypothesis-evaluating treatment effectiveness studies), and the importance of reporting for replicability and totality of evidence considerations.